Moser M, Menard J
Yale University School of Medicine, New Haven, Connecticut.
J Hum Hypertens. 1993 Feb;7 Suppl 1:S50-5.
Data from the Hypertension Treatment Trials do not indicate that the metabolic effects of the medications used, namely diuretics in all and beta-blockers in some, are of great clinical significance. Effects on lipids are mainly short-term (about one year) and the increased incidence of significant hyperglycaemia and/or diabetes in treated compared with control or placebo subjects is < 1% in most trials. The use of these drugs has improved the prognosis of subjects with both severe and less severe hypertension. Despite these findings, it is possible that medications such as the calcium blockers, ACE inhibitors, or multiple-action drugs, e.g. the alpha-beta-blockers which have no negative and possibly have some positive effects on lipids and glucose metabolism, will improve outcome still further. We must await additional long-term trials to determine this. It is possible that combinations of small doses of two different agents from different classes of drugs will prove to be the ideal approach to hypertension management in the future: efficacy is improved and any adverse metabolic effects are minimised.
高血压治疗试验的数据并未表明所用药物(即所有利尿剂以及部分β受体阻滞剂)的代谢效应具有重大临床意义。对血脂的影响主要是短期的(约一年),并且在大多数试验中,与对照组或安慰剂组相比,治疗组中显著高血糖和/或糖尿病的发病率增加不到1%。使用这些药物改善了重度和轻度高血压患者的预后。尽管有这些发现,但诸如钙通道阻滞剂、血管紧张素转换酶抑制剂或多效药物(如对血脂和葡萄糖代谢无负面影响且可能有一些积极影响的α-β受体阻滞剂)等药物仍有可能进一步改善治疗结果。我们必须等待更多的长期试验来确定这一点。未来,小剂量联合使用来自不同类别药物的两种不同药物可能被证明是治疗高血压的理想方法:疗效提高且任何不良代谢效应降至最低。